| Name | Title | Contact Details |
|---|
MRXI Corporation is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aurora Cannabis Inc. is a world-renowned integrated cannabis company with an industry-leading reputation for continuously elevating and setting the global cannabis industry standard. Through our wholly owned subsidiaries, strategic investments, and global partnerships, Aurora provides a wide range of premium quality cannabis and hemp products and services, develops innovative technologies, promotes cannabis consumer health and wellness, and delivers an exceptional customer experience across all its brands. Aurora`s operations span multiple continents and focuses on both the medical and recreational cannabis production and sales, patient education and clinic counselling services, home hydroponic cultivation, extraction technologies and delivery systems, and hemp-based food health products. We operate around the globe pursuing new and emerging cannabis markets where possible through our owned network of import, export and wholesale distributors, and our e-commerce and mobile applications.
Founded in 2003, Valeo Pharma is a Canadian Pharma Company with a long history of successfully driving #healthcareinnovationforcanadians by commercializing pharmaceutical products in Canada and is therapeutically focused on respiratory diseases, neurodegenerative diseases, specialty products, and oncology.
Alliance Boots is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).